Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC
Metersky M, Losier A, Fraulino D, Warnock T, Varley C, Le A, Winthrop K, McArdle J, Shakir S, Khare R. Early Release - Mycobacterium nebraskense Isolated from Patients in Connecticut and Oregon, USA - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2025, 31: 507-515. PMID: 40023800, PMCID: PMC11878316, DOI: 10.3201/eid3103.240608.Peer-Reviewed Original ResearchConceptsNontuberculous mycobacterial pulmonary diseaseMycobacterial pulmonary diseaseAmerican Thoracic Society/Infectious Diseases Society of America criteriaAntimicrobial drug susceptibility testingPulmonary diseaseDrug susceptibility testingRefractory to treatmentClinically significant causeClarithromycin susceptibilitySusceptibility testingConnecticut patientsRespiratory secretionsPatientsNo symptomsOptimum treatmentSignificant causeInfectionHuman casesDiseaseTreatmentCDCClarithromycinCasesClinicM. nebraskense
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply